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Desmoplastic small round cell tumor (DSRCT) is an
uncommon and highly aggressive neoplasm that was first
described by Gerald and Rosai in 1989 [1]. It has typical
clinical, histologic, immunophenotypic, and cytogenetic
features that separate it from other small blue round cell
tumors, including Ewing’s sarcoma (EWS)/primitive
neuroectodermal tumor (PNET), embryonal and alveolar
rhabdomyosarcoma, neuroblastoma, lymphoma, poorly
differentiated carcinoma, Merkel cell carcinoma, and
malignant mesothelioma. As aggressive therapy, including
multi-agent combination chemotherapy, debulking surgical
resection, and radiation therapy, is justified in these patients,
an accurate and early diagnosis is crucial. Some authors
have reported that an increase in serum cancer antigen 125
(CA 125) might be a specific marker for DSRCT, and thus
might permit early diagnosis and therapeutic monitoring of
this fast-growing tumor [2,3]. We describe a young male
who had intra-abdominal DSRCT and high serum CA 125
concentration. We also discuss the significance of elevated
serum CA 125 concentration, and the histogenesis,
cytogenesis, and treatment of this tumor.
CASE PRESENTATION
A 29-year-old Taiwanese male presented to another hospital
with a 2-month history of abdominal distension associated
with constipation, voiding difficulty, and early satiety.
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Desmoplastic small round cell tumor (DSRCT) is a rare and highly aggressive tumor usually involving
the peritoneum. It occurs more commonly in young males and is characterized by distinctive clinical,
histologic, and immunophenotypic features. The histogenesis of DSRCT remains unknown. Coexpression
of epithelial, mesenchymal, and neural antigens in the same cell provides evidence that DSRCT may arise
from a primitive pluripotent stem cell with divergent differentiation. Recently, according to cytogenetic
studies, some authors have proposed that the divergent differentiation of DSRCT may be the result of
the fusion of Ewing’s sarcoma gene and Wilms’ tumor suppressor gene. Clinically, an elevated serum
CA 125 concentration is found in some patients with DSRCT. We present the case of a 29-year-old man
with diffuse intra-abdominal DSRCT and elevated serum CA 125 concentration and briefly review the
relevant literature.
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Computerized tomography (CT) scan of the abdomen and
pelvis revealed a tumor mass 12 cm in diameter in the pelvic
cavity. Colonoscopy and cystoscopy showed external
compression of the rectum, sigmoid colon, and urinary
bladder. Laboratory studies were unremarkable except for
a CA 125 concentration of 882.1 U/mL (normal, < 35 U/mL).
Echo-guided needle biopsy was performed and the
pathologic diagnosis was PNET.
The patient was transferred to our hospital for further
evaluation and treatment. On physical examination, a large,
movable, tender mass was palpated in the lower abdomen.
On ultrasonography and CT scan, there was a huge lobulated
tumor mass between the rectum and the urinary bladder,
with severe external compression of the posterior wall of
the urinary bladder (Figure 1). In addition, mild ascites,
bilateral pleural effusion and multiple nodules in the liver
and lung were noted. A series of nuclear medicine studies
also showed a high probability of bone metastasis in the left
femur, ribs, and mandible. He received combination
chemotherapy (dacarbazine, epirubicin, ifosfamide,
oncovin), which followed the initial treatment for PNET.
After completing six courses of chemotherapy, subsequent
CT scan demonstrated shrinkage of the tumor. Serum CA
125 concentration was normalized to 20.7 U/mL and the
symptoms subsided gradually. Irradiation over the pelvis
and liver was arranged, but the tumor did not show further
change. The patient’s serum CA 125 concentration rose
again, to 69.8 U/mL. Laparotomy was performed to provide
further debulking. However, only excision biopsy was
completed because his condition was made inoperable by
the presence of many white, firm masses with smooth
bosselated surfaces throughout the mesentery (Figure 2)
and the parietal peritoneum over the intestine and bladder.
On microscopic examination, various sized, solid nests
and cords of small blue round cells were embedded in a
hypervascular desmoplastic stroma. The tumor cells were
closely packed and had uniform hyperchromatic nuclei
with inconspicuous nucleoli and scant eosinophilic
cytoplasm (Figure 3). The stroma was dense and collagenous
with scattered spindle cells. Areas of calcification were also
present. Immunohistochemical studies demonstrated
coexpression of cytokeratin, vimentin, desmin, neuron-
specific enolase (NSE), and neurofilament. The desmin was
in a perinuclear dot-like pattern (Figure 4). Electron
microscopically, the tumor cells revealed paranuclear
Figure 1. Computerized tomography scan of the pelvis shows a huge
tumor mass between the rectum and urinary bladder.
Figure 2. Many firm masses with smooth and bosselated surfaces over
the mesentery.
Figure 3. (A) Microscopy shows solid nests of small blue round cells
embedded in a desmoplastic stroma (hematoxylin & eosin; original
magnification × 8). (B) The tumor cells are closely packed and have
uniform hyperchromatic nuclei and scant cytoplasm (hematoxylin &
eosin; original magnification × 80).
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aggregates of intermediate filaments and cellular junctions.
According to these characteristics, the diagnosis was revised
to DSRCT. The fusion of the EWS gene on chromosome 22
and Wilms’ tumor suppressor (WT1) gene on chromosome
11, resulting from the chromosomal translocation t(11;22)
(p13;q12), was detected by reverse transcriptase polymerase
chain reaction (RT-PCR) later at the first hospital.
The patient subsequently underwent another six courses
of chemotherapy with a multi-agent regimen (high-dose
methotrexate alternating with bleomycin, epirubicin,
gemcitabine, and cisplatin) and later received autologous
peripheral stem cell transplantation. The main tumor in the
pelvic cavity partially responded and there was complete
resolution of the hepatic nodules. Unfortunately, recurrence
of the tumor in the liver was noted after 6 months and his
general condition deteriorated rapidly. Whole liver
irradiation was arranged and the epidermal growth factor
receptor-tyrosine kinase inhibitor (EGFR-TKI) gefitinib
(Iressa, ZD1839; AstraZeneca UK Ltd, Cheshire, England)
was prescribed, but in vain. The patient died of liver failure
26 months after initial diagnosis.
DISCUSSION
DSRCT is a rare neoplasm that has a significant male
predilection and usually affects young adults and
adolescents. Clinically, the main tumor mass is usually
located in the abdomen, pelvis, omentum, or mesentery,
with extensive peritoneal involvement. It often spreads
diffusely along the intra-abdominal serosal surface, and
lacks evidence of a visceral primary site. Rare extra-
abdominal sites such as the paratesticular region [4,5],
pleura [6,7], central nervous system [8], ovary [9], hand [10],
and parotid gland [11] have also been described. The most
common complaint of patients is abdominal pain and
abdominal distension accompanied by constipation and
anuresis due to external compression of the tumor. Metastatic
spread and direct implantation into the serosal lining are
not uncommon. Histologically, the tumor is typically
composed of solid nests of undifferentiated small blue
round cells embedded in a desmoplastic stroma. The main
diagnostic feature of these tumors is coexpression of
epithelial (cytokeratin), mesenchymal (vimentin and
desmin), and neural (NSE, neurofilament) markers in the
same cell. The most useful diagnostic marker is desmin,
which is in a perinuclear dot-like or globoid staining pattern
[12]. Ultrastructurally, the tumor cell usually demonstrates
paranuclear aggregates of intermediate filament, consistent
with the perinuclear dot-like staining pattern of desmin.
Secretory lumina, desmosomes, cell processes with
microtubules, and electron-dense granules have also been
described [12,13]. The clinical manifestations, histology,
immunoprofile, and ultrastructural features of our case
were consistent with the typical findings of DSRCT.
The histogenesis of DSRCT is uncertain. The consistent
immunoprofile and predilection for children and adolescents
suggest that it may arise from a primitive pluripotent stem
cell with divergent differentiation. The specific cytogenetic
abnormality in this tumor, t(11;22)(p13;q12), first noted by
Sawyer et al [14], might explain the multidirectional
differentiation of the neoplastic cells. This translocation is
unique to DSRCT, and the breakpoints involve two
chromosomal regions, the EWS gene on 22q12 and the WT1
gene on 11p13. Parkash et al suggested that the divergent
differentiation might be the result of EWS-WT1 fusion,
allowing a combination of neural differentiation of Ewing’s
sarcoma with the multidirectional differentiation of Wilms’
tumor [7]. In addition, the fusion protein appears to induce
expression of platelet-derived growth factor A, a potent
fibroblast growth factor that could contribute to the
desmoplastic stroma formation [15]. Detection of the
transcript by RT-PCR is a helpful method to confirm
diagnosis of the tumor [16].
CA 125 is a high molecular weight glycoprotein. Serum
CA 125 concentration has been shown to be elevated in
cases of ovarian, pancreatic, breast, colon, lung, and
endometrial carcinoma. Several reports have described an
increase in serum CA 125 concentration in patients with
DSRCT [2,3,9,17]. Whether the high serum CA 125 con-
centration is attributable to the tumor cells themselves or to
Figure 4. Immunostaining for desmin shows a typical perinuclear dot-
like pattern. (Original magnification × 80.)
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the mesothelial expression of this antigen is a matter for
argument. In our case, there was a high serum CA 125
concentration, and normalization occurred together with
decreased ascites and shrinkage of the tumor mass after
chemotherapy. Re-elevation of the concentration was
subsequently noted when the tumor grew again. So, CA 125
could be a useful marker for DSRCT and could allow the
clinician to monitor treatment progress.
The initial pathologic diagnosis in our case was PNET at
another institution and the first chemotherapy regimen was
that for PNET. We propose that CA 125 could be a marker
for DSRCT. Genetic testing could be used earlier for small
round cell tumors of unknown origin with elevated CA 125.
If genetic testing identifies the unique findings of DSRCT,
treatment can be started promptly.
DSRCT is a highly aggressive neoplasm with an
extremely poor prognosis. Complete excision of the tumor
is often impossible due to multiple tumor implants in the
peritoneum, and patients usually die of the disease and
widespread metastasis, with a median survival of 17 months
from diagnosis [18]. Survival may be improved by high-
dose multi-drug combination chemotherapy followed by
aggressive surgical resection, radiotherapy, and myelo-
ablative chemotherapy with stem-cell rescue [19–21].
Recently, gefitinib (Iressa, ZD1839), an orally active, selective
EGFR-TKI that blocks signal transduction pathways
involved in the proliferation and survival of cancer cells,
has been developed. Preclinical studies demonstrate that
gefitinib is a promising agent for the treatment of a wide
range of tumors, including non-small-cell lung cancer,
prostate, breast, head and neck, gastric, and colorectal
tumors, and has additive-to-synergistic effects when
combined with radiation or chemotherapy in various cell
lines and xenografts [22]. No clinical data on the use of
gefitinib in the treatment of DSRCT have been reported.
This agent was prescribed in our case, but to no avail.
Further investigation is needed.
The specific cytogenetic features of DSRCT raise the
possibility of monoclonal antibody-based therapy without
significant toxicity to normal tissues. Although detection of
the EWS-WT1 chimeric transcript is specific for DSRCT, its
potential use in detecting minimal residual disease in blood
or bone marrow has not been addressed in published reports.
Modak et al described GD2, which is recognized by the
monoclonal antibody 3F8, and a novel tumor antigen
recognized by the monoclonal antibody 8H9 as two possible
targets for immunotherapy of this tumor [23]. GD2 is a
disialoganglioside that is widely expressed among
neuroectodermal tumors as well as adult sarcomas; 8H9
recognizes a 58 kd surface antigen expressed among
neuroectodermal, mesenchymal, and epithelial tumors,
with restricted expression in normal tissues. Using
immunohistochemistry, 70% of DSRCTs were reactive
to 3F8 and 96% to 8H9 in their study, and both GD2 and the
58 kd antigen were localized to tumor cell membrane and
stroma. As a result, monoclonal antibodies selective for cell
surface tumor-associated antigens may be useful for
diagnosis and therapy of minimal residual disease, as
recently demonstrated in advanced-stage neuroblastoma.
In summary, the clinician should be alert to the possibility
of DSRCT when young men present with huge peritoneal
tumor masses without relation to a particular organ.
Pathologists must keep this entity in mind and make the
correct diagnosis by performing specific immuno-
histochemical, ultrastructural, and cytogenetic studies.
REFERENCES
1. Gerald WL, Rosai J. Case 2. Desmoplastic small cell tumor
with divergent differentiation. Pediatr Pathol 1989;9:
177–83.
2. Ordonez NG, Sahin AA. CA 125 production in desmoplastic
small round cell tumor: report of a case with elevated serum
levels and prominent signet ring morphology. Hum Pathol
1998;29:294–9.
3. Yoshizawa J, Maie M, Eto T, et al. A case of intra-abdominal
desmoplastic small-round-cell tumor with elevated serum
CA125. Pediatr Surg Int 2002;18:238–40.
4. Cummings OW, Ulbright TM, Young RH, et al. Desmoplastic
small round cell tumors of the paratesticular region. A report
of six cases. Am J Surg Pathol 1997;21:219–25.
5. Furman J, Murphy WM, Wajsman Z, Berry AD 3rd. Urogenital
involvement by desmoplastic small round-cell tumor. J Urol
1997;158:1506–9.
6. Bian Y, Jordan AG, Rupp M, et al. Effusion cytology of
desmoplastic small round cell tumor of the pleura. A case
report. Acta Cytol 1993;37:77–82.
7. Parkash V, Gerald WL, Parma A, et al. Desmoplastic small round
cell tumor of the pleura. Am J Surg Pathol 1995;19:659–65.
8. Tison V, Cerasoli S, Morigi F, et al. Intracranial desmoplastic
small-cell tumor. Report of a case. Am J Surg Pathol 1996;20:
112–7.
9. Parker LP, Duong JL, Wharton JT, et al. Desmoplastic small
round cell tumor: report of a case presenting as a primary
ovarian neoplasm. Eur J Gynaecol Oncol 2002;23:199–202.
10. Adsay V, Cheng J, Athanasian E, et al. Primary desmoplastic
small cell tumor of soft tissues and bone of the hand. Am J Surg
Pathol 1999;23:1408–13.
11. Wolf AN, Ladanyi M, Paull G, et al. The expanding clinical
spectrum of desmoplastic small round-cell tumor: a report of
two cases with molecular confirmation. Hum Pathol 1999;30:
430–5.
Desmoplastic small round cell tumor
535Kaohsiung J Med Sci October 2003 • Vol 19 • No 10
12. Ordonez NG. Desmoplastic small round cell tumor: II: an
ultrastructural and immunohistochemical study with
emphasis on new immunohistochemical markers. Am J Surg
Pathol 1998;22:1314–27.
13. Pasquinelli G, Montanaro L, Martinelli GN. Desmoplastic
small round-cell tumor: a case report on the large cell variant
with immunohistochemical, ultrastructural, and molecular
genetic analysis. Ultrastruct Pathol 2000;24:333–7.
14. Sawyer JR, Tryka AF, Lewis JM. A novel reciprocal
chromosome translocation t(11;22)(p13;q12) in an intra-
abdominal desmoplastic small round-cell tumor. Am J Surg
Pathol 1992;16:411–6.
15. Argatoff LH, O’Connell JX, Mathers JA, et al. Detection of the
EWS/WT1 gene fusion by reverse transcriptase-polymerase
chain reaction in the diagnosis of intra-abdominal desmoplastic
small round cell tumor. Am J Surg Pathol 1996;20:406–12.
16. Athale UH, Shurtleff SA, Jenkins JJ, et al. Use of reverse
transcriptase polymerase chain reaction for diagnosis and
staging of alveolar rhabdomyosarcoma, Ewing sarcoma family
of tumors, and desmoplastic small round cell tumor. J Pediatr
Hematol Oncol 2001;23:99–104.
17. Fizazi K, Farhat F, Theodore C, et al. Ca125 and neuron-specific
enolase (NSE) as tumour markers for intra-abdominal
desmoplastic small round-cell tumours. Br J Cancer 1997;75:76–8.
18. Sharma S, Vikram NK, Thulkar S, Goel S. Case of the season.
Desmoplastic small round cell tumor. Semin Roentgenol 2001;
36:3–5.
19. Kushner BH, LaQuaglia MP, Wollner N, et al. Desmoplastic
small round-cell tumor: prolonged progression-free survival
with aggressive multimodality therapy. J Clin Oncol 1996;14:
1526–31.
20. Quaglia MP, Brennan MF. The clinical approach to
desmoplastic small round cell tumor. Surg Oncol 2000;9:77–81.
21. Goodman KA, Wolden SL, La Quaglia MP, Kushner BH.
Whole abdominopelvic radiotherapy for desmoplastic small
round-cell tumor. Int J Radiat Oncol Biol Phys 2002;54:170–6.
22. Ranson M. ZD1839 (Iressa): for more than just non-small cell
lung cancer. Oncologist 2002;7(Suppl 4):16–24.
23. Modak S, Gerald W, Cheung NK. Disialoganglioside GD2 and
a novel tumor antigen: potential targets for immunotherapy
of desmoplastic small round cell tumor. Med Pediatr Oncol
2002;39:547–51.
